India's greenfield bulk drugs drive amidst shift from China

The Indian pharmaceutical sector is poised for a substantial makeover with the inauguration of 27 greenfield plants dedicated to manufacturing bulk drugs. These plants signify a pivotal shift in India's pharmaceutical landscape and an in-your-face statement to the heavy import dependence on China, reports The Pharma Letter’s India correspondent.

The government's approach to the COVID-19 pandemic was an opportunity for transformation, said Rajesh Kumar Singh, from the Department for Promotion of Industry and Internal Trade. Underscoring the administration's commitment to bolstering self-reliance, fostering innovation, and enhancing infrastructure, Mr Singh said the Production Linked Incentive (PLI) scheme was conceived to promote localization and value addition within India's pharmaceutical and MedTech sector,

Speaking at an event, Mr Singh said it aims to mitigate over-dependence on critical resources from specific geographic regions.